Skip to main content
Divisions
Molecular diagnostics and distributed qPCR solutions.
Complete PCR solutions for molecular diagnostics.
Customised NGS for next-generation molecular insights.
Technologies
Instruments
Miniaturised qPCR devices with superior performance
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
About us
Vision & Values
Our identity and the principles that guide the Group.
Numbers and Certifications
Reliability, performance and standards that define our work.
Leadership
The management team leading Helyx Industries.
About Helyx
The history, evolution and culture of our Group.
Insights
See all Insights
13 April 2026 | Technology and Applied Research
PCR Diagnostics: Technological Challenges and Solutions
qPCR remains a key technology in molecular diagnostics, but challenges such as signal drift, reagent stability, quality control and throughput limitations continue to hinder its widespread adoption. This article examines the most significant solutions currently available, integrated platforms, ambient-stable reagents, cloud computing and AI, with a focus on Helyx Industries’ Hyris platform.
30 March 2026 | Market and Industry Trends
The economic impact of multiplex diagnostics in hospitals
Decentralised multiplex diagnostics can improve cost-effectiveness in hospitals not because the cost per test is lower, but because it reduces the costs associated with waiting: isolation, hospital stays, delays in decision-making and the overload on the central laboratory.
News
Press releases
13 April 2026
Pubblicata la documentazione per l'Assemblea Ordinaria degli Azionisti
Press releases
11 April 2026
Convocazione dell'assemblea ordinaria degli azionisti
Press releases
23 March 2026
Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio e il bilancio consolidato al 31 dicembre 2025
Updates and announcements
23 March 2026
Helyx Automation Accelerates: First Order Received for the New Proprietary Liquid Handling System
Investors
Helyx Industries is an industrial group active in the field of genetics. It has proprietary technologies and processes for complete and integrated solutions in molecular biology, from PCR to NGS. Through its divisions, it offers its solutions directly to diagnostic laboratories and hospitals or provides its services to diagnostic and industrial partners. Helyx Industries is listed on Euronext Growth in Milan.
Read more
Contact us
IT
EN
IT
EN
Divisions
Molecular diagnostics and distributed qPCR solutions.
Hyris System™
Agrifood & Nutraceuticals Catalogue
Development and OEM services
Complete PCR solutions for molecular diagnostics.
Human Health Catalogue
Customised NGS for next-generation molecular insights.
Customised NGS panels
Compatible areas & technologies
Technologies
Instruments
Miniaturised qPCR devices with superior performance
bCUBE™
bGATE™
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
bAPP™
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
Sagitta™
Stable multiplex reagents
About Us
Vision & Values
Our identity and the principles that guide the Group.
Vision
Mission
Numbers and Certifications
Reliability, performance and standards that define our work.
Facts and Figures
Certifications
Leadership
The management team leading Helyx Industries.
People
About Helyx
The history, evolution and culture of our Group.
Our History
Timeline
Insights
News
Updates & announcements
Commercial news announced by Helyx Industries.
Read all
Press releases
Regulated and price-sensitive press releases.
Read all
Scientific Publications
Research, studies and published scientific papers.
Read all
Investors
Helyx Industries
Helyx Industries is an integrated biotech group with proprietary technologies that develops diagnostic solutions, focusing on public health, distributed diagnostics and molecular innovation.
Download Pitch Deck
Overview
Corporate Governance
Information for shareholders
Financial data
Press releases
Financial calendar
Shareholders' meeting
Analyst Coverage
Warrant
Internal dealing
Investment Agreement with GCF
Concluded extraordinary transactions
IPO
Investor Relations Contacts
Contacts
11 April, 2026
Press releases
Convocazione dell'assemblea ordinaria degli azionisti
Link
23 March 2026
Helyx Automation Accelerates: First Order Received for the New Proprietary Liquid Handling System
CONTINUE TO READING
11 February 2026
Helyx Industries enters the Next Generation Sequencing (NGS) market and joins Neonatal Screening project in Puglia
CONTINUE TO READING
19 January 2026
Helyx Industries is born: a rebranding that consolidates a new three-division industrial structure
CONTINUE TO READING
07 August 2025
Papillomavirus Screening: Self-sampling with HPV-Selfy is Effective and Well-Accepted by Women, a New Study Confirms.
CONTINUE TO READING
06 August 2025
COMMUNICATION OF CONCESSION FOR POR FESR 2021-2027
CONTINUE TO READING
09 May 2025
Ulisse Biomed supports the fight against malaria
CONTINUE TO READING
14 April 2025
The innovative soul of Ulisse Biomed: the research and development that drives our future
CONTINUE TO READING
12 March 2025
Hyris expands testing rapid technology aimed at supporting the fight against malaria
CONTINUE TO READING
29 January 2025
New partnership agreement with Capebio
CONTINUE TO READING
20 January 2025
NEW DISTRIBUTION AGREEMENT WITH MONTEBELLO DIAGNOSTICS
CONTINUE TO READING
23 March 2026
Helyx Automation Accelerates: First Order Received for the New Proprietary Liquid Handling System
CONTINUE TO READING
11 February 2026
Helyx Industries enters the Next Generation Sequencing (NGS) market and joins Neonatal Screening project in Puglia
CONTINUE TO READING
19 January 2026
Helyx Industries is born: a rebranding that consolidates a new three-division industrial structure
CONTINUE TO READING
07 August 2025
Papillomavirus Screening: Self-sampling with HPV-Selfy is Effective and Well-Accepted by Women, a New Study Confirms.
CONTINUE TO READING
06 August 2025
COMMUNICATION OF CONCESSION FOR POR FESR 2021-2027
CONTINUE TO READING
09 May 2025
Ulisse Biomed supports the fight against malaria
CONTINUE TO READING
14 April 2025
The innovative soul of Ulisse Biomed: the research and development that drives our future
CONTINUE TO READING
12 March 2025
Hyris expands testing rapid technology aimed at supporting the fight against malaria
CONTINUE TO READING
29 January 2025
New partnership agreement with Capebio
CONTINUE TO READING
20 January 2025
NEW DISTRIBUTION AGREEMENT WITH MONTEBELLO DIAGNOSTICS
CONTINUE TO READING
